Anxiety Disorders (Pediatric) Research Study

This study examines whether an antibiotic, d-cycloserine (DCS), boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety. CBT has been shown to be effective for the treatment of social anxiety in children and adults, but even after treatment, approximately 40% may remain diagnosable. All participants will receive 12 weekly CBT sessions. In addition to receiving the CBT, participants will be randomly assigned (similar to a coin toss) to receive either DCS or a placebo (sugar pill). The pill will be taken 1-2 hours prior to each of the 12 CBT sessions. The pill is taken only on the 12 therapy days. If you are ages 7-55 with a social phobia, you may be eligible for the study.

Organization: 
NIMH
Principal Investigator: 
Jennifer A. Cameron, Ph.D.
Eligibility Criteria: 
  1. Subjects between 8 yrs of age (preadolescents) and under 55 yrs of age.
  2. Subjects medically healthy.
  3. Able to give informed consent.
  4. Not on psychotropic meds for a minimum of 6 weeks for fluoxetine; a minimum of 1 week for PRN benzodiazepines and beta blockers, and a minimum of 3 weeks for all other psychotropic meds.
  5. Subjects diagnosed with DSM IV symptoms of social phobia, generalized or specific type.
Exclusion Criteria: 
  1. Current major depressive disorder.
  2. Lifetime diagnosis of psychotic disorder, bipolar disorder, eating disorder, mental retardation, substance or alcohol dependence (other than nicotine); active suicidal ideation.
  3. Current or lifetime history of a neurological disorder (other than tic disorders, febrile seizures of infancy), seizure disorder.
  4. Any unstable medical condition.
  5. Use of any psychoactive substance in the past 30 days.
Contact: 
(800) 411-1222, prpl@mail.cc.nih.gov
Location: 
Bethesda, MD
State: 
Maryland

FAQ